[Skip to Content]
[Skip to Content Landing]

The Skin of Color Society’s Meeting the Challenge Summit, 2022Diversity in Dermatology Clinical Trials Proceedings

To identify the key insights or developments described in this article
1 Credit CME

Importance  Clinical trials remain the cornerstone for determining the safety and efficacy of an intervention. A diverse participant pool in dermatology clinical trials is critical to ensure that results are generalizable among the patient population who will ultimately depend on the efficacy of the intervention. The Skin of Color Society hosted the inaugural Meeting the Challenge Summit: Diversity in Dermatology Clinical Trials in Washington, DC, from June 10 to 11, 2022. The summit was an interactive and collaborative effort to advance discussions regarding the need for broader inclusion of racial and ethnic minority patients in dermatology clinical trials.

Observations  The summit focused on 3 principal areas: (1) understanding the current clinical trials landscape; (2) breaking down patient, clinician, industry, and regulatory barriers; and (3) effecting change through a diversity-focused strategy. The program hosted thought-provoking panel talks and discussions with various stakeholder groups, including a keynote presentation from the family of Henrietta Lacks.

Conclusions and Relevance  Panel discussions and insightful presentations from physicians, industry leaders, community trailblazers, and patients fostered new collaborations. The summit provided recommendations and suggested strategies for future initiatives designed to increase the representation of minority individuals in dermatology clinical trials.

Sign in to take quiz and track your certificates

Buy This Activity
Our websites may be periodically unavailable between 7:00pm CT June 10, 2023 and 1:00am CT June 11, 2023 for regularly scheduled maintenance.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: April 2, 2023.

Published Online: May 24, 2023. doi:10.1001/jamadermatol.2023.1285

Corresponding Author: Valerie M. Harvey, MD, MPH, Hampton Roads Center for Dermatology, 860 Omni Blvd, Ste 112, Newport News, VA 23606 (valerieharvey10@gmail.com).

Author Contributions: Dr Harvey had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Cobb, Heath, McKinley-Grant, Callender, Adamson, Brown, Desai, Glass, Jaleel, Okoye, Taylor, Harvey.

Acquisition, analysis, or interpretation of data: Cobb, Byrd, Jaleel, Okoye, Taylor, Harvey.

Drafting of the manuscript: Cobb, Callender, Harvey.

Critical revision of the manuscript for important intellectual content: Cobb, Heath, Byrd, McKinley-Grant, Adamson, Brown, Desai, Glass, Jaleel, Okoye, Taylor, Harvey.

Statistical analysis: Cobb.

Obtained funding: Cobb.

Administrative, technical, or material support: Cobb, Brown, Okoye, Harvey.

Supervision: Cobb, Heath, McKinley-Grant, Callender, Desai, Jaleel, Taylor.

Conflict of Interest Disclosures: Dr Byrd reported being the recipient of the Skin of Color Society’s Career Development Award to support professional development and research efforts, the Society for Investigative Dermatology Freinkel Diversity Fellowship Award, and the Robert A. Winn Diversity in Clinical Trials Career Development Award funded by the Bristol Myers Squibb Foundation; she is also a consultant for Senté and Sonoma Biotherapeutics outside the submitted work. Dr McKinley-Grant reported personal fees from Janssen during the conduct of the study and served as the past president of the Skin of Color Society. Dr Callender reported grants from AbbVie, Dermavant, Galderma, Janssen, L’Oreal, Lilly, and UCB during the conduct of the study; grants from Acne Store, Almirall, Aerolase, Avava, Avita Medical, Beiersdorf, Cutera, Epi Health, IKNOW Skincare, Incyte, Juenesse Aesthetics, OrthoDerm, Pfizer, Prollenium, Scientis, Sente, SkinBetter Science, SkinCeuticals, Symatese, and Teoxane, as well as personal fees from UpToDate outside the submitted work; and serving as a founding member and past president of the Skin of Color Society. Dr Desai reported serving as past president of the Skin of Color Society and is the president-elect of the American Academy of Dermatology; he also serves as a researcher and/or consultant for Pfizer, Lilly, AbbVie, Bristol Myers Squibb, and Galderma. Dr Glass reported personal fees from Pfizer, UCB, and AbbVie outside the submitted work and served as past president of the Skin of Color Society. Dr Jaleel reported grants from Pfizer, the Skin of Color Society, the Dermatology Foundation, and the National Institutes of Health Building Interdisciplinary Research Careers in Women’s Health (K12HD043446), as well as personal fees from UCB, Lilly, Novartis, and ChemoCentryx outside the submitted work. Dr Okoye reported grants from Janssen and Pfizer; personal fees from Unilever, Novartis, Lilly, AbbVie, Sanofi, and UCB; and serving on the board of the HS Foundation outside the submitted work. Dr Taylor reported personal fees from AbbVie, Arcutis Biotherapeutics, Armis, Avita Medical, Beiersdorf, Biorez, Bristol Myers Squibb, Cara Therapeutics, Dior, Lilly, EPI Health, Evolus, Galderma, Glogetter, Hugel America, Johnson & Johnson, L’Oreal, MedScape, MJH Life Sciences, Pfizer, Piction Health, Sanofi, Scientis, UCB, Vichy Laboratoires, McGraw Hill, and Mercer Strategies; grants from Allergan Aesthetics, Concert Pharmaceuticals, Croma-Pharma GmbH, Lilly, Pfizer, all outside the submitted work; and serving as past president of the Skin of Color Society. Dr Harvey reported grants from AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb, Dermavant, Eli Lilly, Galderma, Google, Janssen, L’Oreal, Revision Skincare, Sanofi/Regeneron, UCB, and Vial during the conduct of the study; serving on the advisory boards of UCB, Skinceuticals, AbbVie, and Bristol Myers Squibb; serving as a consultant for L’Oreal, Novartis, and Unilever; and serving as the current president of the Skin of Color Society. No other disclosures were reported.

Disclaimer: Dr Adamson is an Associate Editor and Web Editor of JAMA Dermatology but was not involved in any of the decisions regarding review of the manuscript or its acceptance.

Additional Contributions: We thank the family of Henrietta Lacks for sharing their advice and experiences, as well as the many clinical trial participants who shared their stories at the summit. We also thank Janice Ayarzagoitia, MA, and Kimberly Miller, BA, of TREX & Medical Society Management, which manages the Skin of Color Society, for their help with the summit. Finally, we thank the Meeting the Challenge Summit: Diversity in Dermatology Clinical Trials task force members and the Skin of Color Society officers and board of directors for their support.

Additional Information: The Skin of Color Society’s Meeting the Challenge Summit was supported by AbbVie, Janssen, Bristol Myers Squibb, Lilly, Arcutis Biotherapeutics, Dermavant, Galderma, Google, Sanofi/Regeneron, L’Oreal, Revision Skincare, UCB, and Vial.

Skloot  R .  The Immortal Life of Henrietta Lacks. Broadway Books; 2011.
Kamal  K , Imadojemu  S , Charrow  A .  Why diversity in dermatology clinical trials should no longer be optional: dismantling structural racism in dermatology.   JAMA Dermatol. 2022;158(4):353-354. doi:10.1001/jamadermatol.2021.5190PubMedGoogle ScholarCrossref
National Institutes of Health Revitalization Act of 1993, HR 4, 103rd Cong (1993).Pub L No. 103-43. Accessed April 10, 2023. https://www.congress.gov/bill/103rd-congress/house-bill/4
Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs: guidance for industry. US Food and Drug Administration. November 2020. Accessed April 10, 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial
Turner  BE , Steinberg  JR , Weeks  BT , Rodriguez  F , Cullen  MR .  Race/ethnicity reporting and representation in US clinical trials: a cohort study.   Lancet Reg Health Am. 2022;11:11. doi:10.1016/j.lana.2022.100252PubMedGoogle ScholarCrossref
Charrow  A , Xia  FD , Joyce  C , Mostaghimi  A .  Diversity in dermatology clinical trials: a systematic review.   JAMA Dermatol. 2017;153(2):193-198. doi:10.1001/jamadermatol.2016.4129PubMedGoogle ScholarCrossref
Chen  V , Akhtar  S , Zheng  C , Kumaresan  V , Nouri  K .  Assessment of changes in diversity in dermatology clinical trials between 2010-2015 and 2015-2020: a systematic review.   JAMA Dermatol. 2022;158(3):288-292. doi:10.1001/jamadermatol.2021.5596PubMedGoogle ScholarCrossref
Diversity and inclusion in clinical trials. National Institute on Minority Health and Health Disparities. Updated March 15, 2023. Accessed April 10, 2023. https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html.
Unger  JM , Gralow  JR , Albain  KS , Ramsey  SD , Hershman  DL .  Patient income level and cancer clinical trial participation: a prospective survey study.   JAMA Oncol. 2016;2(1):137-139. doi:10.1001/jamaoncol.2015.3924PubMedGoogle ScholarCrossref
Herndon  JE  II , Kornblith  AB , Holland  JC , Paskett  ED .  Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.   Psychooncology. 2013;22(2):315-323.PubMedGoogle Scholar
Rivers  D , August  EM , Sehovic  I , Lee Green  B , Quinn  GP .  A systematic review of the factors influencing African Americans’ participation in cancer clinical trials.   Contemp Clin Trials. 2013;35(2):13-32. doi:10.1016/j.cct.2013.03.007PubMedGoogle ScholarCrossref
Unger  JM , Hershman  DL , Till  C ,  et al.  “When offered to participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials.   J Natl Cancer Inst. 2021;113(3):244-257. doi:10.1093/jnci/djaa155PubMedGoogle ScholarCrossref
Ford  JG , Howerton  MW , Lai  GY ,  et al.  Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.   Cancer. 2008;112(2):228-242. doi:10.1002/cncr.23157PubMedGoogle ScholarCrossref
Clark  LT , Watkins  L , Piña  IL ,  et al.  Increasing diversity in clinical trials: overcoming critical barriers.   Curr Probl Cardiol. 2019;44(5):148-172. doi:10.1016/j.cpcardiol.2018.11.002PubMedGoogle ScholarCrossref
Wendler  D , Kington  R , Madans  J ,  et al.  Are racial and ethnic minorities less willing to participate in health research?   PLoS Med. 2006;3(2):e19. doi:10.1371/journal.pmed.0030019PubMedGoogle ScholarCrossref
Diversity in medicine: facts and figures 2019. Association of American Medical Colleges. Accessed April 10, 2023. https://www.aamc.org/data-reports/workforce/report/diversity-facts-figures.
QuickFacts population estimates. US Census Bureau. July 21, 2021. Accessed April 10, 2023. https://www.census.gov/quickfacts/fact/table/US/PST045221.
Marrast  LM , Zallman  L , Woolhandler  S , Bor  DH , McCormick  D .  Minority physicians’ role in the care of underserved patients: diversifying the physician workforce may be key in addressing health disparities.   JAMA Intern Med. 2014;174(2):289-291. doi:10.1001/jamainternmed.2013.12756PubMedGoogle ScholarCrossref
Katz  RV , Green  BL , Kressin  NR , Claudio  C , Wang  MQ , Russell  SL .  Willingness of minorities to participate in biomedical studies: confirmatory findings from a follow-up study using the Tuskegee Legacy Project Questionnaire.   J Natl Med Assoc. 2007;99(9):1052-1060.PubMedGoogle Scholar
Takeshita  J , Wang  S , Loren  AW ,  et al.  Association of racial/ethnic and gender concordance between patients and physicians with patient experience ratings.   JAMA Netw Open. 2020;3(11):e2024583. doi:10.1001/jamanetworkopen.2020.24583PubMedGoogle ScholarCrossref
Michaud  S , Needham  J , Sundquist  S ,  et al.  Patient and patient group engagement in cancer clinical trials: a stakeholder charter.   Curr Oncol. 2021;28(2):1447-1458. doi:10.3390/curroncol28020137PubMedGoogle ScholarCrossref
Hwang  TJ , Brawley  OW .  New federal incentives for diversity in clinical trials.   N Engl J Med. 2022;387(15):1347-1349. doi:10.1056/NEJMp2209043PubMedGoogle ScholarCrossref
Raths  D . New law requires Medicaid coverage of clinical trial participation. Healthcare Innovation. January 4, 2022. Accessed April 10, 2023. https://www.hcinnovationgroup.com/policy-value-based-care/medicare-medicaid/news/21251951/new-law-requires-medicaid-coverage-of-clinical-trial-participation
Vose  J .  Minority enrollment to clinical trials: road to increased access.   Oncology (Williston Park). 2021;35(3):107. doi:10.46883/ONC.2021.3503.0107PubMedGoogle ScholarCrossref
Asabor  EN , Cohen  JM , Aysola  J .  Why increased diversity in dermatologic clinical trials is not inherently ethical-an evidence-based, community-engaged approach to diverse trial recruitment.   JAMA Dermatol. 2022;158(10):1219. doi:10.1001/jamadermatol.2022.3109PubMedGoogle ScholarCrossref
Lester  J , Wintroub  B , Linos  E .  Disparities in academic dermatology.   JAMA Dermatol. 2016;152(8):878-879. doi:10.1001/jamadermatol.2016.1533PubMedGoogle ScholarCrossref
Rubin  E ; Editors.  Striving for diversity in research studies.   N Engl J Med. 2021;385(15):1429-1430. doi:10.1056/NEJMe2114651PubMedGoogle ScholarCrossref
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience

Lookup An Activity


My Saved Searches

You currently have no searches saved.


My Saved Courses

You currently have no courses saved.